Tetanus toxoid-derived MHC class II-peptide complex (TT-MHC II complex)

The Tetanus toxoid-derived MHC class II-peptide complex is a molecular assembly consisting of immunodominant peptides from the tetanus toxin protein (such as P2 and P30) bound to Major Histocompatibility Complex (MHC) Class II molecules on the surface of antigen-presenting cells (APCs). These complexes are characterized as "universal" epitopes because they can be presented by a wide variety of human leukocyte antigen (HLA) alleles, allowing them to be recognized by the immune systems of a vast majority of the global population. In therapeutic contexts, these complexes are utilized to leverage pre-existing immunity; since most individuals have been vaccinated against tetanus, they possess a pool of memory CD4+ T cells that can rapidly respond to these specific pMHC presentations. By incorporating TT-derived peptides into conjugate vaccines or cancer immunotherapies, researchers can "redirect" these memory T cells to provide essential help—such as cytokine secretion and CD40 ligand expression—to B cells or CD8+ T cells targeting a different, often less immunogenic, antigen. This strategy is fundamental to the efficacy of many pediatric conjugate vaccines and is a key strategy in the development of novel therapeutic vaccines for cancer and neurodegenerative diseases.

Other names

Tetanus toxoid carrier protein–derived peptides presented on MHC class IIUniversal T-cell epitopes of tetanus toxoidTT-derived MHC II epitopesP2/P30-MHC II complexesTetanus toxoid helper peptides

Recruitment and activation of pre-existing memory CD4+ T cells to provide T-cell help (via cytokines and CD40L) for B-cell activation or cytotoxic T-cell priming.